drug
erenumab
Marketedupdated 3mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying erenumab
- phase2Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
- phase4Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
- phase3Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
- phase3Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
- —Migraine Survey in Gulf Region
- —Aimovig Pregnancy Exposure Registry
- phase2Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH
- phase3Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
News(3)
- Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsSlate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…fiercebiotech · 1d ago
- A new Westlake-backed biotech takes aim at migrainesVedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.biopharma_dive · 2mo ago
- Study data convince Lundbeck to push new migraine drug forwardA possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.biopharma_dive · 2mo ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that